Cargando…
Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361401/ https://www.ncbi.nlm.nih.gov/pubmed/35958425 http://dx.doi.org/10.3389/fcvm.2022.981544 |
| _version_ | 1784764525219676160 |
|---|---|
| author | Xu, Keman Khan, Mohsin Yu, Jun Snyder, Nathaniel W. Wu, Sheng Vazquez-Padron, Roberto I. Wang, Hong Yang, Xiaofeng |
| author_facet | Xu, Keman Khan, Mohsin Yu, Jun Snyder, Nathaniel W. Wu, Sheng Vazquez-Padron, Roberto I. Wang, Hong Yang, Xiaofeng |
| author_sort | Xu, Keman |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9361401 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93614012022-08-10 Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics Xu, Keman Khan, Mohsin Yu, Jun Snyder, Nathaniel W. Wu, Sheng Vazquez-Padron, Roberto I. Wang, Hong Yang, Xiaofeng Front Cardiovasc Med Cardiovascular Medicine Frontiers Media S.A. 2022-07-26 /pmc/articles/PMC9361401/ /pubmed/35958425 http://dx.doi.org/10.3389/fcvm.2022.981544 Text en Copyright © 2022 Xu, Khan, Yu, Snyder, Wu, Vazquez-Padron, Wang and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Cardiovascular Medicine Xu, Keman Khan, Mohsin Yu, Jun Snyder, Nathaniel W. Wu, Sheng Vazquez-Padron, Roberto I. Wang, Hong Yang, Xiaofeng Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| title | Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| title_full | Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| title_fullStr | Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| title_full_unstemmed | Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| title_short | Editorial: Insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| title_sort | editorial: insights in cardiovascular therapeutics: 2021 – cell death, cardiovascular injuries, and novel targets of cardiovascular therapeutics |
| topic | Cardiovascular Medicine |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361401/ https://www.ncbi.nlm.nih.gov/pubmed/35958425 http://dx.doi.org/10.3389/fcvm.2022.981544 |
| work_keys_str_mv | AT xukeman editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT khanmohsin editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT yujun editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT snydernathanielw editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT wusheng editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT vazquezpadronrobertoi editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT wanghong editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics AT yangxiaofeng editorialinsightsincardiovasculartherapeutics2021celldeathcardiovascularinjuriesandnoveltargetsofcardiovasculartherapeutics |